Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1571666

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1571666

Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment, By End-use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Cervical Cancer Treatment Market Growth & Trends:

The global cervical cancer treatment market size is expected to reach USD 11.74 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased treatment penetration and rising disease incidence are projected to drive the market growth over the next few years. Although, sexually transmitted HPV is a major cause, the disease can also be triggered by other factors, such as oral contraceptives, multiple sexual partners, smoking, and HIV infection. There are more than 100 strains of HPV, 13 of which are high-risk or cancerous. Squamous cell carcinoma is the most common type and it accounts for nearly 85% of the overall cases.

The differentiation between squamous cell carcinoma and adenocarcinoma is based on the histology, as observed under the microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of squamous and glandular tissues. Products for cervical cancer can be broadly classified into prevention and treatment. Preventive options involve vaccines against HPV. Currently, there are two commercial vaccines - Gardasil and Cervarix. Treatment options include biologics, such as Avastin and generics like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin, and doxorubicin. The development of targeted therapeutics with improved efficacy and reduced cost remains a key unmet need of this market. Nevertheless, expanding focus on the research and development in oncology, including cervical cancer, indicate a promising future for this market.

Cervical Cancer Treatment Market Report Highlights:

  • Squamous cell carcinoma type dominated the market and accounted for the largest revenue share of 71.1% in 2023. This growth is attributed to persistent infection with high-risk human papillomavirus (HPV) subtypes, mainly HPV 16 and 18, which account for most cases.
  • Chemotherapy treatment led the market and accounted for the largest revenue share of 33.9% in 2023. This growth is attributed to the advancements in drug development that have significantly enhanced treatment options for cervical adenocarcinoma.
  • Hospitals & clinics segment dominated the market and accounted for the largest revenue share of 65.0% in 2023. This growth is attributed to the enhanced delivery procedures in hospitals & clinics with offerings such as targeted therapy, radiation therapy, immunotherapy, minimally invasive surgeries, and many other methods.
  • The North America cervical cancer treatment market dominated the global market and accounted for the largest revenue share of 39.4% in 2023.
Show more
Product Code: GVR-2-68038-718-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cervical Cancer Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cervical Cancer Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cervical Cancer Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cervical Cancer Treatment Market: Type Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Squamous Cell Carcinoma
    • 4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Adenocarcinoma
    • 4.4.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Adenosquamous Carcinoma
    • 4.5.1. Adenosquamous Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Types
    • 4.6.1. Other Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cervical Cancer Treatment Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cervical Cancer Treatment Market: Treatment Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Radiation Therapy
    • 5.3.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. External Beam Radiation Therapy (EBRT)
      • 5.3.2.1. External Beam Radiation Therapy (EBRT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Brachytherapy
      • 5.3.3.1. Brachytherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Cisplatin
      • 5.4.2.1. Cisplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Carboplatin
      • 5.4.3.1. Carboplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Paclitaxel
      • 5.4.4.1. Paclitaxel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Other Chemotherapeutic Agents
      • 5.4.5.1. Other Chemotherapeutic Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Bevacizumab (Avastin)
      • 5.5.2.1. Bevacizumab (Avastin) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Other Targeted Therapies
      • 5.5.3.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Pembrolizumab (Keytruda)
      • 5.6.2.1. Pembrolizumab (Keytruda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. Other Immune Checkpoint Inhibitors
      • 5.6.3.1. Other Immune Checkpoint Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other Therapies
    • 5.7.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cervical Cancer Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cervical Cancer Treatment Market: End Use Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals & Clinics
    • 6.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ambulatory Surgery Centers
    • 6.4.1. Ambulatory Surgery Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cervical Cancer Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Cervical Cancer Treatment Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Merck & Co., Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bristol-Myers Squibb Company
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. F. Hoffmann-La Roche Ltd
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Pfizer Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Eli Lilly and Company.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. AstraZeneca
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. GSK plc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. AbbVie Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Johnson & Johnson Services, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!